Difference between revisions of "HAEM5:Volunteer Assignments and Opportunities"
Jump to navigation
Jump to search
[unchecked revision] | [unchecked revision] |
Line 2: | Line 2: | ||
|+WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (4th Edition) Content | |+WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (4th Edition) Content | ||
|- | |- | ||
− | !Disease (5th Edition)!!Page Type!!Author!!Date Assigned to Author!!Target Completion Date!!Author Content (Pending or Complete)!!Date Completed by Author!!Associate Editor!!Date of Last Editor Review | + | !Disease (5th Edition)!!Page Type!!Author (5th edition)!!Date Assigned to Author (5th Edition)!!Target Completion Date (5th Edition)!!Author Content (5th Edition)(Pending or Complete)!!Date Completed by Author (5th Edition)!!Associate Editor!!Date of Last Editor Review!!Notes |
− | !Correlated Prior Disease Name (4th Edition)! | + | !Correlated Prior Disease Name (4th Edition) |
+ | !Correlated Prior Author (4th Edition) | ||
|- | |- | ||
|CHAPTER 2 (MYELOID PROLIFERATIONS AND NEOPLASMS) | |CHAPTER 2 (MYELOID PROLIFERATIONS AND NEOPLASMS) | ||
Line 10: | Line 11: | ||
| | | | ||
----<br /> | ----<br /> | ||
+ | | | ||
| | | | ||
| | | | ||
Line 19: | Line 21: | ||
| | | | ||
|- | |- | ||
− | |Clonal haematopoiesis||Disease|| || || || || ||Fabiola Quintero-Rivera (FQR)|| | + | |Clonal haematopoiesis||Disease|| || || || || ||Fabiola Quintero-Rivera (FQR)|| || |
− | | | + | | |
+ | | | ||
|- | |- | ||
− | |Clonal cytopenias of undetermined significance||Disease|| || || || || ||FQR|| | + | |Clonal cytopenias of undetermined significance||Disease|| || || || || ||FQR|| || |
− | | | + | | |
+ | | | ||
|- | |- | ||
− | |Chronic myeloid leukaemia||Disease||Jack Reid, MD (University of California, Irvine) Mark Evans, MD (University of California, Irvine) Fabiola Quintero-Rivera, MD (University of California, Irvine)|| || || || ||FQR|| | + | |Chronic myeloid leukaemia||Disease||Jack Reid, MD (University of California, Irvine) Mark Evans, MD (University of California, Irvine) Fabiola Quintero-Rivera, MD (University of California, Irvine)|| || || || ||FQR|| || |
− | | | + | | |
+ | | | ||
|- | |- | ||
− | |Chronic neutrophilic leukaemia||Disease||Anamaria Munteanu, MD, Ph.D**, Harbor-UCLA Medical Center, Joseph J. Merlo Jr, MD. Ph.D**, Ashion Analytics, Fabiola Quintero-Rivera, University of California Irvine <nowiki>**</nowiki>contributed equally|| || || || ||FQR|| | + | |Chronic neutrophilic leukaemia||Disease||Anamaria Munteanu, MD, Ph.D**, Harbor-UCLA Medical Center, Joseph J. Merlo Jr, MD. Ph.D**, Ashion Analytics, Fabiola Quintero-Rivera, University of California Irvine <nowiki>**</nowiki>contributed equally|| || || || ||FQR|| || |
− | | | + | | |
+ | | | ||
|- | |- | ||
− | |Chronic eosinophilic leukaemia||Disease||Chelsea D. Kramish; Daynna J.Wolff Pending Review*|| || || || ||FQR|| | + | |Chronic eosinophilic leukaemia||Disease||Chelsea D. Kramish; Daynna J.Wolff Pending Review*|| || || || ||FQR|| || |
− | | | + | | |
+ | | | ||
|- | |- | ||
− | |Polycythaemia vera||Disease||Gokce A. Toruner, MD, PhD UT MD Anderson Cancer Center|| || || || ||FQR|| | + | |Polycythaemia vera||Disease||Gokce A. Toruner, MD, PhD UT MD Anderson Cancer Center|| || || || ||FQR|| || |
− | | | + | | |
+ | | | ||
|- | |- | ||
− | |Essential thrombocythaemia||Disease||Rebecca Smith, PhD, Director, Genetics Associates, Nashville, TN|| || || || ||FQR|| | + | |Essential thrombocythaemia||Disease||Rebecca Smith, PhD, Director, Genetics Associates, Nashville, TN|| || || || ||FQR|| || |
− | | | + | | |
+ | | | ||
|- | |- | ||
− | |Primary myelofibrosis||Disease||T. Niroshi Senaratne, UCLA|| || || || ||FQR|| | + | |Primary myelofibrosis||Disease||T. Niroshi Senaratne, UCLA|| || || || ||FQR|| || |
− | | | + | | |
+ | | | ||
|- | |- | ||
− | |Juvenile myelomonocytic leukaemia||Disease|| '''Sarah Rapisardo, PhD, FACMG''' |Assistant Professor, Pathology Associate Director | Division of Molecular Pathology, Genetics and Genomics Duke University Health System Clinical Laboratories|| || || || ||FQR|| | + | |Juvenile myelomonocytic leukaemia||Disease|| '''Sarah Rapisardo, PhD, FACMG''' |Assistant Professor, Pathology Associate Director | Division of Molecular Pathology, Genetics and Genomics Duke University Health System Clinical Laboratories|| || || || ||FQR|| || |
− | | | + | | |
+ | | | ||
|- | |- | ||
− | |Myeloproliferative neoplasm, NOS||Disease||Thomas Lee, MD, PhD, University of California, Los Angeles|| || || || ||FQR|| | + | |Myeloproliferative neoplasm, NOS||Disease||Thomas Lee, MD, PhD, University of California, Los Angeles|| || || || ||FQR|| || |
− | | | + | | |
+ | | | ||
|- | |- | ||
− | |Cutaneous mastocytosis||Disease||S. Shawn Liu, MD, PhD and Thuy Phung, MD, PhD|| || || || ||FQR|| | + | |Cutaneous mastocytosis||Disease||S. Shawn Liu, MD, PhD and Thuy Phung, MD, PhD|| || || || ||FQR|| || |
− | | | + | | |
+ | | | ||
|- | |- | ||
− | |Systemic mastocytosis||Disease||'''Abdullah Osme, MD,''' University Hospitals Cleveland Medical Center, Case Western Reserve University '''Shashi Shetty, Ph.D. FACMG, FCCMG,''' University Hospitals Cleveland Medical Center, Case Western Reserve University|| || || || ||FQR|| | + | |Systemic mastocytosis||Disease||'''Abdullah Osme, MD,''' University Hospitals Cleveland Medical Center, Case Western Reserve University '''Shashi Shetty, Ph.D. FACMG, FCCMG,''' University Hospitals Cleveland Medical Center, Case Western Reserve University|| || || || ||FQR|| || |
− | | | + | | |
+ | | | ||
|- | |- | ||
− | |Mast cell sarcoma||Disease||Jordan Lowery, MD and Thuy Phung, MD, PhD Department of Pathology, University of South Alabama, Mobile, AL|| || || || ||FQR|| | + | |Mast cell sarcoma||Disease||Jordan Lowery, MD and Thuy Phung, MD, PhD Department of Pathology, University of South Alabama, Mobile, AL|| || || || ||FQR|| || |
− | | | + | | |
+ | | | ||
|- | |- | ||
− | |Myelodysplastic neoplasm with low blasts and 5q deletion||Disease|| || || || || ||FQR|| | + | |Myelodysplastic neoplasm with low blasts and 5q deletion||Disease|| || || || || ||FQR|| || |
− | | | + | | |
+ | | | ||
|- | |- | ||
− | |Myelodysplastic neoplasm with low blasts and SF3B1 mutation||Disease|| || || || || ||FQR|| | + | |Myelodysplastic neoplasm with low blasts and SF3B1 mutation||Disease|| || || || || ||FQR|| || |
− | | | + | | |
+ | | | ||
|- | |- | ||
− | |Myelodysplastic neoplasm with biallelic TP53 inactivation||Disease|| || || || || ||FQR|| | + | |Myelodysplastic neoplasm with biallelic TP53 inactivation||Disease|| || || || || ||FQR|| || |
− | | | + | | |
+ | | | ||
|- | |- | ||
− | |Myelodysplastic neoplasm with low blasts||Disease|| || || || || ||FQR|| | + | |Myelodysplastic neoplasm with low blasts||Disease|| || || || || ||FQR|| || |
− | | | + | | |
+ | | | ||
|- | |- | ||
− | |Myelodysplastic neoplasm, hypoplastic||Disease|| || || || || ||FQR|| | + | |Myelodysplastic neoplasm, hypoplastic||Disease|| || || || || ||FQR|| || |
− | | | + | | |
+ | | | ||
|- | |- | ||
− | |Myelodysplastic neoplasm with increased blasts||Disease||Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG Division of Human Genetics, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH, 45229, USA.|| || || || ||FQR|| | + | |Myelodysplastic neoplasm with increased blasts||Disease||Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG Division of Human Genetics, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH, 45229, USA.|| || || || ||FQR|| || |
− | | | + | | |
+ | | | ||
|- | |- | ||
− | |Childhood myelodysplastic neoplasm with low blasts||Disease||Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG Division of Human Genetics, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH, 45229, USA.|| || || || ||FQR|| | + | |Childhood myelodysplastic neoplasm with low blasts||Disease||Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG Division of Human Genetics, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH, 45229, USA.|| || || || ||FQR|| || |
− | | | + | | |
+ | | | ||
|- | |- | ||
− | |Childhood myelodysplastic neoplasm with increased blasts||Disease||Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG Division of Human Genetics, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH, 45229, USA.|| || || || ||FQR|| | + | |Childhood myelodysplastic neoplasm with increased blasts||Disease||Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG Division of Human Genetics, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH, 45229, USA.|| || || || ||FQR|| || |
− | | | + | | |
+ | | | ||
|- | |- | ||
− | |Chronic myelomonocytic leukaemia||Disease||Linsheng Zhang, MD, PhD|| || || || ||FQR|| | + | |Chronic myelomonocytic leukaemia||Disease||Linsheng Zhang, MD, PhD|| || || || ||FQR|| || |
− | | | + | | |
+ | | | ||
|- | |- | ||
− | |Myelodysplastic/myeloproliferative neoplasm with neutrophilia||Disease||Linsheng Zhang, MD, PhD|| || || || ||FQR|| | + | |Myelodysplastic/myeloproliferative neoplasm with neutrophilia||Disease||Linsheng Zhang, MD, PhD|| || || || ||FQR|| || |
− | | | + | | |
+ | | | ||
|- | |- | ||
− | |Myelodysplastic/myeloproliferative neoplasm with SF3B1 mutation and thrombocytosis||Disease||Anamaria Munteanu, MD, Ph.D, Harbor-UCLA Medical Center, Fabiola Quintero-Rivera, University of California Irvine|| || || || ||FQR|| | + | |Myelodysplastic/myeloproliferative neoplasm with SF3B1 mutation and thrombocytosis||Disease||Anamaria Munteanu, MD, Ph.D, Harbor-UCLA Medical Center, Fabiola Quintero-Rivera, University of California Irvine|| || || || ||FQR|| || |
− | | | + | | |
+ | | | ||
|- | |- | ||
− | |Myelodysplastic/myeloproliferative neoplasm, NOS||Disease||Ruth MacKinnon PhD Victorian Cancer Cytogenetics Service Melbourne, Australia|| || || || ||FQR|| | + | |Myelodysplastic/myeloproliferative neoplasm, NOS||Disease||Ruth MacKinnon PhD Victorian Cancer Cytogenetics Service Melbourne, Australia|| || || || ||FQR|| || |
− | | | + | | |
+ | | | ||
|- | |- | ||
− | |Myeloid/lymphoid neoplasm with PDGFRA rearrangement||Disease||Jay Alden, DO|| || || || ||FQR|| | + | |Myeloid/lymphoid neoplasm with PDGFRA rearrangement||Disease||Jay Alden, DO|| || || || ||FQR|| || |
− | | | + | | |
+ | | | ||
|- | |- | ||
− | |Myeloid/lymphoid neoplasm with PDGFRB rearrangement||Disease||Christopher Sullivan, MD, MPH and Daynna J. Wolff, PhD|| || || || ||FQR|| | + | |Myeloid/lymphoid neoplasm with PDGFRB rearrangement||Disease||Christopher Sullivan, MD, MPH and Daynna J. Wolff, PhD|| || || || ||FQR|| || |
− | | | + | | |
+ | | | ||
|- | |- | ||
− | |Myeloid/lymphoid neoplasm with FGFR1 rearrangement||Disease||Yanna Ding, MD PhD|| || || || ||FQR|| | + | |Myeloid/lymphoid neoplasm with FGFR1 rearrangement||Disease||Yanna Ding, MD PhD|| || || || ||FQR|| || |
− | | | + | | |
+ | | | ||
|- | |- | ||
− | |Myeloid/lymphoid neoplasm with JAK2 rearrangement||Disease||Jessica Snider, M.D. and Daynna J. Wolff, PhD|| || || || ||FQR|| | + | |Myeloid/lymphoid neoplasm with JAK2 rearrangement||Disease||Jessica Snider, M.D. and Daynna J. Wolff, PhD|| || || || ||FQR|| || |
− | | | + | | |
+ | | | ||
|- | |- | ||
− | |Myeloid/lymphoid neoplasm with FLT3 rearrangement||Disease|| || || || || ||FQR|| | + | |Myeloid/lymphoid neoplasm with FLT3 rearrangement||Disease|| || || || || ||FQR|| || |
− | | | + | | |
+ | | | ||
|- | |- | ||
− | |Myeloid/lymphoid neoplasm with ETV6::ABL1 fusion||Disease|| || || || || ||FQR|| | + | |Myeloid/lymphoid neoplasm with ETV6::ABL1 fusion||Disease|| || || || || ||FQR|| || |
− | | | + | | |
+ | | | ||
|- | |- | ||
− | |Myeloid/lymphoid neoplasms with other tyrosine kinase fusion genes||Disease|| || || || || ||FQR|| | + | |Myeloid/lymphoid neoplasms with other tyrosine kinase fusion genes||Disease|| || || || || ||FQR|| || |
− | | | + | | |
+ | | | ||
|- | |- | ||
|Acute promyelocytic leukaemia with PML::RARA fusion | |Acute promyelocytic leukaemia with PML::RARA fusion | ||
Line 123: | Line 157: | ||
| | | | ||
|Jennelle Hodge (JH)/ Malini Sathanoori (MS) | |Jennelle Hodge (JH)/ Malini Sathanoori (MS) | ||
+ | | | ||
| | | | ||
| | | | ||
Line 135: | Line 170: | ||
| | | | ||
|JH_MS | |JH_MS | ||
+ | | | ||
| | | | ||
| | | | ||
Line 147: | Line 183: | ||
| | | | ||
|JH_MS | |JH_MS | ||
+ | | | ||
| | | | ||
| | | | ||
Line 159: | Line 196: | ||
| | | | ||
|JH_MS | |JH_MS | ||
+ | | | ||
| | | | ||
| | | | ||
Line 171: | Line 209: | ||
| | | | ||
|JH_MS | |JH_MS | ||
+ | | | ||
| | | | ||
| | | | ||
Line 183: | Line 222: | ||
| | | | ||
|JH_MS | |JH_MS | ||
+ | | | ||
| | | | ||
| | | | ||
Line 195: | Line 235: | ||
| | | | ||
|JH_MS | |JH_MS | ||
+ | | | ||
| | | | ||
| | | | ||
Line 207: | Line 248: | ||
| | | | ||
|JH_MS | |JH_MS | ||
+ | | | ||
| | | | ||
| | | | ||
Line 219: | Line 261: | ||
| | | | ||
|JH_MS | |JH_MS | ||
+ | | | ||
| | | | ||
| | | | ||
Line 231: | Line 274: | ||
| | | | ||
|JH_MS | |JH_MS | ||
+ | | | ||
| | | | ||
| | | | ||
Line 243: | Line 287: | ||
| | | | ||
|JH_MS | |JH_MS | ||
+ | | | ||
| | | | ||
| | | | ||
Line 255: | Line 300: | ||
| | | | ||
|JH_MS | |JH_MS | ||
+ | | | ||
| | | | ||
| | | | ||
Line 267: | Line 313: | ||
| | | | ||
|JH_MS | |JH_MS | ||
+ | | | ||
| | | | ||
| | | | ||
Line 279: | Line 326: | ||
| | | | ||
|JH_MS | |JH_MS | ||
+ | | | ||
| | | | ||
| | | | ||
Line 291: | Line 339: | ||
| | | | ||
|JH_MS | |JH_MS | ||
+ | | | ||
| | | | ||
| | | | ||
Line 303: | Line 352: | ||
| | | | ||
|JH_MS | |JH_MS | ||
+ | | | ||
| | | | ||
| | | | ||
Line 315: | Line 365: | ||
| | | | ||
|JH_MS | |JH_MS | ||
+ | | | ||
| | | | ||
| | | | ||
Line 327: | Line 378: | ||
| | | | ||
|JH_MS | |JH_MS | ||
+ | | | ||
| | | | ||
| | | | ||
Line 339: | Line 391: | ||
| | | | ||
|JH_MS | |JH_MS | ||
+ | | | ||
| | | | ||
| | | | ||
Line 351: | Line 404: | ||
| | | | ||
|JH_MS | |JH_MS | ||
+ | | | ||
| | | | ||
| | | | ||
Line 363: | Line 417: | ||
| | | | ||
|JH_MS | |JH_MS | ||
+ | | | ||
| | | | ||
| | | | ||
Line 375: | Line 430: | ||
| | | | ||
|JH_MS | |JH_MS | ||
+ | | | ||
| | | | ||
| | | | ||
Line 387: | Line 443: | ||
| | | | ||
|JH_MS | |JH_MS | ||
+ | | | ||
| | | | ||
| | | | ||
Line 399: | Line 456: | ||
| | | | ||
|JH_MS | |JH_MS | ||
+ | | | ||
| | | | ||
| | | | ||
Line 411: | Line 469: | ||
| | | | ||
|JH_MS | |JH_MS | ||
+ | | | ||
| | | | ||
| | | | ||
Line 423: | Line 482: | ||
| | | | ||
|JH_MS | |JH_MS | ||
+ | | | ||
| | | | ||
| | | | ||
Line 435: | Line 495: | ||
| | | | ||
|JH_MS | |JH_MS | ||
+ | | | ||
| | | | ||
| | | | ||
Line 447: | Line 508: | ||
| | | | ||
|JH_MS | |JH_MS | ||
+ | | | ||
| | | | ||
| | | | ||
Line 459: | Line 521: | ||
| | | | ||
|JH_MS | |JH_MS | ||
+ | | | ||
| | | | ||
| | | | ||
Line 471: | Line 534: | ||
| | | | ||
|JH_MS | |JH_MS | ||
+ | | | ||
| | | | ||
| | | | ||
Line 483: | Line 547: | ||
| | | | ||
|JH_MS | |JH_MS | ||
+ | | | ||
| | | | ||
| | | | ||
Line 495: | Line 560: | ||
| | | | ||
|JH_MS | |JH_MS | ||
+ | | | ||
| | | | ||
| | | | ||
Line 507: | Line 573: | ||
| | | | ||
|JH_MS | |JH_MS | ||
+ | | | ||
| | | | ||
| | | | ||
Line 516: | Line 583: | ||
| | | | ||
----<br /> | ----<br /> | ||
+ | | | ||
| | | | ||
| | | | ||
Line 533: | Line 601: | ||
| | | | ||
|Greg Corboy (GC) | |Greg Corboy (GC) | ||
+ | | | ||
| | | | ||
| | | | ||
Line 545: | Line 614: | ||
| | | | ||
|GC | |GC | ||
+ | | | ||
| | | | ||
| | | | ||
Line 557: | Line 627: | ||
| | | | ||
|GC | |GC | ||
+ | | | ||
| | | | ||
| | | | ||
Line 569: | Line 640: | ||
| | | | ||
|GC | |GC | ||
+ | | | ||
| | | | ||
| | | | ||
Line 581: | Line 653: | ||
| | | | ||
|GC | |GC | ||
+ | | | ||
| | | | ||
| | | | ||
Line 593: | Line 666: | ||
| | | | ||
|GC | |GC | ||
+ | | | ||
| | | | ||
| | | | ||
Line 605: | Line 679: | ||
| | | | ||
|GC | |GC | ||
+ | | | ||
| | | | ||
| | | | ||
Line 617: | Line 692: | ||
| | | | ||
|GC | |GC | ||
+ | | | ||
| | | | ||
| | | | ||
Line 629: | Line 705: | ||
| | | | ||
|GC | |GC | ||
+ | | | ||
| | | | ||
| | | | ||
Line 641: | Line 718: | ||
| | | | ||
|GC | |GC | ||
+ | | | ||
| | | | ||
| | | | ||
Line 653: | Line 731: | ||
| | | | ||
|GC | |GC | ||
+ | | | ||
| | | | ||
| | | | ||
Line 662: | Line 741: | ||
| | | | ||
----<br /> | ----<br /> | ||
+ | | | ||
| | | | ||
| | | | ||
Line 679: | Line 759: | ||
| | | | ||
|GC | |GC | ||
+ | | | ||
| | | | ||
| | | | ||
Line 691: | Line 772: | ||
| | | | ||
|GC | |GC | ||
+ | | | ||
| | | | ||
| | | | ||
Line 703: | Line 785: | ||
| | | | ||
|GC | |GC | ||
+ | | | ||
| | | | ||
| | | | ||
Line 715: | Line 798: | ||
| | | | ||
|GC | |GC | ||
+ | | | ||
| | | | ||
| | | | ||
Line 727: | Line 811: | ||
| | | | ||
|GC | |GC | ||
+ | | | ||
| | | | ||
| | | | ||
Line 739: | Line 824: | ||
| | | | ||
|Holli Drendel (HD) | |Holli Drendel (HD) | ||
+ | | | ||
| | | | ||
| | | | ||
Line 751: | Line 837: | ||
| | | | ||
|HD | |HD | ||
+ | | | ||
| | | | ||
| | | | ||
Line 763: | Line 850: | ||
| | | | ||
|HD | |HD | ||
+ | | | ||
| | | | ||
| | | | ||
Line 775: | Line 863: | ||
| | | | ||
|HD | |HD | ||
+ | | | ||
| | | | ||
| | | | ||
Line 787: | Line 876: | ||
| | | | ||
|HD | |HD | ||
+ | | | ||
| | | | ||
| | | | ||
Line 799: | Line 889: | ||
| | | | ||
|HD | |HD | ||
+ | | | ||
| | | | ||
| | | | ||
Line 811: | Line 902: | ||
| | | | ||
|HD | |HD | ||
+ | | | ||
| | | | ||
| | | | ||
Line 823: | Line 915: | ||
| | | | ||
|HD | |HD | ||
+ | | | ||
| | | | ||
| | | | ||
Line 835: | Line 928: | ||
| | | | ||
|HD | |HD | ||
+ | | | ||
| | | | ||
| | | | ||
Line 847: | Line 941: | ||
| | | | ||
|HD | |HD | ||
+ | | | ||
| | | | ||
| | | | ||
Line 859: | Line 954: | ||
| | | | ||
|HD | |HD | ||
+ | | | ||
| | | | ||
| | | | ||
Line 871: | Line 967: | ||
| | | | ||
|HD | |HD | ||
+ | | | ||
| | | | ||
| | | | ||
Line 883: | Line 980: | ||
| | | | ||
|HD | |HD | ||
+ | | | ||
| | | | ||
| | | | ||
Line 895: | Line 993: | ||
| | | | ||
|HD | |HD | ||
+ | | | ||
| | | | ||
| | | | ||
Line 900: | Line 999: | ||
|- | |- | ||
|Monoclonal B-cell lymphocytosis||Disease|| || || || || ||Shivani Golem (SG) | |Monoclonal B-cell lymphocytosis||Disease|| || || || || ||Shivani Golem (SG) | ||
+ | | || | ||
+ | | | ||
| | | | ||
− | |||
|- | |- | ||
− | |Chronic lymphocytic leukaemia/small lymphocytic lymphoma||Disease||Jamie Nagy, PhD, University of Iowa Honey Reddi, PhD|| || || || ||SG|| | + | |Chronic lymphocytic leukaemia/small lymphocytic lymphoma||Disease||Jamie Nagy, PhD, University of Iowa Honey Reddi, PhD|| || || || ||SG|| || |
− | | | + | | |
+ | | | ||
|- | |- | ||
− | |Hairy cell leukaemia||Disease||*Snehal Patel, MD, PhD|| || || || ||SG|| | + | |Hairy cell leukaemia||Disease||*Snehal Patel, MD, PhD|| || || || ||SG|| || |
− | | | + | | |
+ | | | ||
|- | |- | ||
− | |Splenic marginal zone lymphoma||Disease||*Snehal Patel, MD, PhD|| || || || ||SG|| | + | |Splenic marginal zone lymphoma||Disease||*Snehal Patel, MD, PhD|| || || || ||SG|| || |
− | | | + | | |
+ | | | ||
|- | |- | ||
− | |Splenic diffuse red pulp small B-cell lymphoma||Disease||*Snehal Patel, MD, PhD|| || || || ||SG|| | + | |Splenic diffuse red pulp small B-cell lymphoma||Disease||*Snehal Patel, MD, PhD|| || || || ||SG|| || |
− | | | + | | |
+ | | | ||
|- | |- | ||
|Splenic B-cell lymphoma/leukaemia with prominent nucleoli | |Splenic B-cell lymphoma/leukaemia with prominent nucleoli | ||
Line 923: | Line 1,027: | ||
| | | | ||
|SG | |SG | ||
+ | | | ||
| | | | ||
| | | | ||
Line 935: | Line 1,040: | ||
| | | | ||
|SG | |SG | ||
+ | | | ||
| | | | ||
| | | | ||
Line 947: | Line 1,053: | ||
| | | | ||
|SG | |SG | ||
+ | | | ||
| | | | ||
| | | | ||
Line 959: | Line 1,066: | ||
| | | | ||
|SG | |SG | ||
+ | | | ||
| | | | ||
| | | | ||
Line 971: | Line 1,079: | ||
| | | | ||
|SG | |SG | ||
+ | | | ||
| | | | ||
| | | | ||
Line 983: | Line 1,092: | ||
| | | | ||
|SG | |SG | ||
+ | | | ||
| | | | ||
| | | | ||
Line 995: | Line 1,105: | ||
| | | | ||
|SG | |SG | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,007: | Line 1,118: | ||
| | | | ||
|SG | |SG | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,019: | Line 1,131: | ||
| | | | ||
|SG | |SG | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,031: | Line 1,144: | ||
| | | | ||
|SG | |SG | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,043: | Line 1,157: | ||
| | | | ||
|SG | |SG | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,055: | Line 1,170: | ||
| | | | ||
|SG | |SG | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,067: | Line 1,183: | ||
| | | | ||
|SG | |SG | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,079: | Line 1,196: | ||
| | | | ||
|SG | |SG | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,091: | Line 1,209: | ||
| | | | ||
|SG | |SG | ||
+ | | | ||
| | | | ||
| | | | ||
| | | | ||
|- | |- | ||
− | |Diffuse large B-cell lymphoma, NOS||Disease||Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center|| || || || ||GC|| | + | |Diffuse large B-cell lymphoma, NOS||Disease||Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center|| || || || ||GC|| || |
− | | | + | | |
+ | | | ||
|- | |- | ||
− | |T-cell/histiocyte-rich large B-cell lymphoma||Disease|| || || || || ||GC|| | + | |T-cell/histiocyte-rich large B-cell lymphoma||Disease|| || || || || ||GC|| || |
− | | | + | | |
+ | | | ||
|- | |- | ||
− | |Diffuse large B-cell lymphoma / high grade B-cell lymphoma with MYC and BCL2 rearrangements||Disease||Kate Berry, MBBS, BBus (Hons), Pathology Queensland|| || || || ||GC|| | + | |Diffuse large B-cell lymphoma / high grade B-cell lymphoma with MYC and BCL2 rearrangements||Disease||Kate Berry, MBBS, BBus (Hons), Pathology Queensland|| || || || ||GC|| || |
− | | | + | | |
+ | | | ||
|- | |- | ||
− | |ALK-positive large B-cell lymphoma||Disease||Manando Nakasaki, MD, PhD (University of California, Irvine) Fabiola Quintero-Rivera, MD, FACMG (University of California, Irvine)|| || || || ||GC|| | + | |ALK-positive large B-cell lymphoma||Disease||Manando Nakasaki, MD, PhD (University of California, Irvine) Fabiola Quintero-Rivera, MD, FACMG (University of California, Irvine)|| || || || ||GC|| || |
− | | | + | | |
+ | | | ||
|- | |- | ||
− | |Large B-cell lymphoma with IRF4 rearrangement||Disease||*Afia Hasnain, MBBS, PhD|| || || || ||GC|| | + | |Large B-cell lymphoma with IRF4 rearrangement||Disease||*Afia Hasnain, MBBS, PhD|| || || || ||GC|| || |
− | | | + | | |
+ | | | ||
|- | |- | ||
− | |High grade B-cell lymphoma with 11q aberrations||Disease||Lauren Shealy, MD, Medical University of South Carolina Daynna Wolff, PhD, Medical University of South Carolina|| || || || ||GC|| | + | |High grade B-cell lymphoma with 11q aberrations||Disease||Lauren Shealy, MD, Medical University of South Carolina Daynna Wolff, PhD, Medical University of South Carolina|| || || || ||GC|| || |
− | | | + | | |
+ | | | ||
|- | |- | ||
− | |Lymphomatoid granulomatosis||Disease|| || || || || ||GC|| | + | |Lymphomatoid granulomatosis||Disease|| || || || || ||GC|| || |
− | | | + | | |
+ | | | ||
|- | |- | ||
− | |EBV-positive diffuse large B-cell lymphoma||Disease|| || || || || ||GC|| | + | |EBV-positive diffuse large B-cell lymphoma||Disease|| || || || || ||GC|| || |
− | | | + | | |
+ | | | ||
|- | |- | ||
− | |Diffuse large B-cell lymphoma associated with chronic inflammation||Disease|| || || || || ||GC|| | + | |Diffuse large B-cell lymphoma associated with chronic inflammation||Disease|| || || || || ||GC|| || |
− | | | + | | |
+ | | | ||
|- | |- | ||
− | |Fibrin-associated large B-cell lymphoma||Disease|| || || || || ||GC|| | + | |Fibrin-associated large B-cell lymphoma||Disease|| || || || || ||GC|| || |
− | | | + | | |
+ | | | ||
|- | |- | ||
− | |Fluid overload-associated large B-cell lymphoma||Disease|| || || || || ||GC|| | + | |Fluid overload-associated large B-cell lymphoma||Disease|| || || || || ||GC|| || |
− | | | + | | |
+ | | | ||
|- | |- | ||
− | |Plasmablastic lymphoma||Disease||Mark Evans, MD (University of California, Irvine) Fabiola Quintero-Rivera, MD (University of California, Irvine)|| || || || ||GC|| | + | |Plasmablastic lymphoma||Disease||Mark Evans, MD (University of California, Irvine) Fabiola Quintero-Rivera, MD (University of California, Irvine)|| || || || ||GC|| || |
− | | | + | | |
+ | | | ||
|- | |- | ||
− | |Primary large B-cell lymphoma of immune-privileged sites||Disease||Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center|| || || || ||GC|| | + | |Primary large B-cell lymphoma of immune-privileged sites||Disease||Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center|| || || || ||GC|| || |
− | | | + | | |
+ | | | ||
|- | |- | ||
− | |Primary cutaneous diffuse large B-cell lymphoma, leg type||Disease|| || || || || ||GC|| | + | |Primary cutaneous diffuse large B-cell lymphoma, leg type||Disease|| || || || || ||GC|| || |
− | | | + | | |
+ | | | ||
|- | |- | ||
− | |Intravascular large B-cell lymphoma||Disease||Kate Berry, MBBS, BBus (Hons), Pathology Queensland|| || || || ||GC|| | + | |Intravascular large B-cell lymphoma||Disease||Kate Berry, MBBS, BBus (Hons), Pathology Queensland|| || || || ||GC|| || |
− | | | + | | |
+ | | | ||
|- | |- | ||
− | |Primary mediastinal large B-cell lymphoma||Disease|| || || || || ||GC|| | + | |Primary mediastinal large B-cell lymphoma||Disease|| || || || || ||GC|| || |
− | | | + | | |
+ | | | ||
|- | |- | ||
− | |Mediastinal grey zone lymphoma||Disease|| || || || || ||GC|| | + | |Mediastinal grey zone lymphoma||Disease|| || || || || ||GC|| || |
− | | | + | | |
+ | | | ||
|- | |- | ||
− | |High-grade B-cell lymphoma, NOS||Disease||Aiko Otsubo, PhD, Indiana University|| || || || ||GC|| | + | |High-grade B-cell lymphoma, NOS||Disease||Aiko Otsubo, PhD, Indiana University|| || || || ||GC|| || |
− | | | + | | |
+ | | | ||
|- | |- | ||
− | |Burkitt lymphoma||Disease||Becky Leung, MBBS (Hons), BSc, Pathology Queensland|| || || || ||GC|| | + | |Burkitt lymphoma||Disease||Becky Leung, MBBS (Hons), BSc, Pathology Queensland|| || || || ||GC|| || |
− | | | + | | |
+ | | | ||
|- | |- | ||
− | |Primary effusion lymphoma||Disease|| || || || || ||GC|| | + | |Primary effusion lymphoma||Disease|| || || || || ||GC|| || |
− | | | + | | |
+ | | | ||
|- | |- | ||
− | |KSHV/HHV8-positive diffuse large B-cell lymphoma||Disease|| || || || || ||GC|| | + | |KSHV/HHV8-positive diffuse large B-cell lymphoma||Disease|| || || || || ||GC|| || |
− | | | + | | |
+ | | | ||
|- | |- | ||
− | |KSHV/HHV8-positive germinotropic lymphoproliferative disorder||Disease|| || || || || ||GC|| | + | |KSHV/HHV8-positive germinotropic lymphoproliferative disorder||Disease|| || || || || ||GC|| || |
− | | | + | | |
+ | | | ||
|- | |- | ||
− | |Hyperplasias arising in immune deficiency/dysregulation||Disease|| || || || || ||GC|| | + | |Hyperplasias arising in immune deficiency/dysregulation||Disease|| || || || || ||GC|| || |
− | | | + | | |
+ | | | ||
|- | |- | ||
− | |Polymorphic lymphoproliferative disorders arising in immune deficiency / dysregulation||Disease||Anna Shestakova, MD, PhD, Fellow, University of Utah/ARUP Laboratories Fabiola Quintero-Rivera, MD, Professor, University of California Irvine (UCI)|| || || || ||GC|| | + | |Polymorphic lymphoproliferative disorders arising in immune deficiency / dysregulation||Disease||Anna Shestakova, MD, PhD, Fellow, University of Utah/ARUP Laboratories Fabiola Quintero-Rivera, MD, Professor, University of California Irvine (UCI)|| || || || ||GC|| || |
− | | | + | | |
+ | | | ||
|- | |- | ||
− | |EBV-positive mucocutaneous ulcer||Disease|| || || || || ||GC|| | + | |EBV-positive mucocutaneous ulcer||Disease|| || || || || ||GC|| || |
− | | | + | | |
+ | | | ||
|- | |- | ||
− | |Lymphomas arising in immune deficiency / dysregulation||Disease|| || || || || ||GC|| | + | |Lymphomas arising in immune deficiency / dysregulation||Disease|| || || || || ||GC|| || |
− | | | + | | |
+ | | | ||
|- | |- | ||
− | |Inborn error of immunity-associated lymphoid proliferations and lymphomas||Disease|| || || || || ||GC|| | + | |Inborn error of immunity-associated lymphoid proliferations and lymphomas||Disease|| || || || || ||GC|| || |
− | | | + | | |
+ | | | ||
|- | |- | ||
− | |Classic Hodgkin lymphoma||Disease||Patricia V. Hernandez, M.D., Washington University School of Medicine|| || || || ||GC|| | + | |Classic Hodgkin lymphoma||Disease||Patricia V. Hernandez, M.D., Washington University School of Medicine|| || || || ||GC|| || |
− | | | + | | |
+ | | | ||
|- | |- | ||
− | |Nodular lymphocyte predominant Hodgkin lymphoma||Disease|| || || || || ||GC|| | + | |Nodular lymphocyte predominant Hodgkin lymphoma||Disease|| || || || || ||GC|| || |
− | | | + | | |
+ | | | ||
|- | |- | ||
|Cold agglutinin disease | |Cold agglutinin disease | ||
Line 1,190: | Line 1,338: | ||
| | | | ||
|SG | |SG | ||
+ | | | ||
| | | | ||
| | | | ||
| | | | ||
|- | |- | ||
− | |IgM monoclonal gammopathy of undetermined significance||Disease|| || || || || ||SG|| | + | |IgM monoclonal gammopathy of undetermined significance||Disease|| || || || || ||SG|| || |
− | | | + | | |
+ | | | ||
|- | |- | ||
− | |Non-IgM monoclonal gammopathy of undetermined significance||Disease|| || || || || ||SG|| | + | |Non-IgM monoclonal gammopathy of undetermined significance||Disease|| || || || || ||SG|| || |
− | | | + | | |
+ | | | ||
|- | |- | ||
|Monoclonal gammopathy of renal significance||Disease|| || || || || ||SG | |Monoclonal gammopathy of renal significance||Disease|| || || || || ||SG | ||
+ | | || | ||
+ | | | ||
| | | | ||
− | |||
|- | |- | ||
|Immunoglobulin-related (AL) amyloidosis||Disease||Heather E. Williams, PhD, MS, PgD, ErCLG|| || || || ||SG | |Immunoglobulin-related (AL) amyloidosis||Disease||Heather E. Williams, PhD, MS, PgD, ErCLG|| || || || ||SG | ||
+ | | || | ||
+ | | | ||
| | | | ||
− | |||
|- | |- | ||
|Monoclonal immunoglobulin deposition disease||Disease||Chen Yang, MD, PhD, University of Michigan|| || || || ||SG | |Monoclonal immunoglobulin deposition disease||Disease||Chen Yang, MD, PhD, University of Michigan|| || || || ||SG | ||
+ | | || | ||
+ | | | ||
| | | | ||
− | |||
|- | |- | ||
|Mu heavy chain disease||Disease|| || || || || ||SG | |Mu heavy chain disease||Disease|| || || || || ||SG | ||
+ | | || | ||
+ | | | ||
| | | | ||
− | |||
|- | |- | ||
|Gamma heavy chain disease||Disease||Manisha Brahmbhatt-Sutariya Asst. Professor, Dept. of Pathology and Human Anatomy Technical Supervisor, Clinical Genetics Laboratory Loma Linda University, Medical Center, CA|| || || || ||SG | |Gamma heavy chain disease||Disease||Manisha Brahmbhatt-Sutariya Asst. Professor, Dept. of Pathology and Human Anatomy Technical Supervisor, Clinical Genetics Laboratory Loma Linda University, Medical Center, CA|| || || || ||SG | ||
+ | | || | ||
+ | | | ||
| | | | ||
− | |||
|- | |- | ||
|Alpha heavy chain disease||Disease|| || || || || ||SG | |Alpha heavy chain disease||Disease|| || || || || ||SG | ||
+ | | || | ||
+ | | | ||
| | | | ||
− | |||
|- | |- | ||
|Plasmacytoma||Disease|| || || || || ||SG | |Plasmacytoma||Disease|| || || || || ||SG | ||
+ | | || | ||
+ | | | ||
| | | | ||
− | |||
|- | |- | ||
|Plasma cell myeloma / multiple myeloma||Disease||*Huan Mo, MD, MS *Zhenya Tang, MD, PhD The University Of Texas MD Anderson Cancer Center, Department of Hematopathology, Houston, Texas|| || || || ||SG | |Plasma cell myeloma / multiple myeloma||Disease||*Huan Mo, MD, MS *Zhenya Tang, MD, PhD The University Of Texas MD Anderson Cancer Center, Department of Hematopathology, Houston, Texas|| || || || ||SG | ||
+ | | || | ||
+ | | | ||
| | | | ||
− | |||
|- | |- | ||
|Plasma cell neoplasms with associated paraneoplastic syndrome||Disease||Sohini Anand, MBBS Tharanga Niroshini Senaratne, PhD|| || || || ||SG | |Plasma cell neoplasms with associated paraneoplastic syndrome||Disease||Sohini Anand, MBBS Tharanga Niroshini Senaratne, PhD|| || || || ||SG | ||
+ | | || | ||
+ | | | ||
| | | | ||
− | |||
|- | |- | ||
|CHAPTER 5 (T-CELL AND NK-CELL LYMPHOID PROLIFERATIONS AND LYMPHOMAS) | |CHAPTER 5 (T-CELL AND NK-CELL LYMPHOID PROLIFERATIONS AND LYMPHOMAS) | ||
Line 1,241: | Line 1,401: | ||
| | | | ||
----<br /> | ----<br /> | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,251: | Line 1,412: | ||
|- | |- | ||
|Kikuchi-Fujimoto disease||Disease|| || || || || ||Sumi Kitahara (SK) | |Kikuchi-Fujimoto disease||Disease|| || || || || ||Sumi Kitahara (SK) | ||
+ | | || | ||
+ | | | ||
| | | | ||
− | |||
|- | |- | ||
− | |Autoimmune lymphoproliferative syndrome||Disease|| || || || || ||SK|| | + | |Autoimmune lymphoproliferative syndrome||Disease|| || || || || ||SK|| || |
− | | | + | | |
+ | | | ||
|- | |- | ||
− | |Indolent T-lymphoblastic proliferation||Disease|| || || || || ||SK|| | + | |Indolent T-lymphoblastic proliferation||Disease|| || || || || ||SK|| || |
− | | | + | | |
+ | | | ||
|- | |- | ||
− | |T-lymphoblastic leukaemia / lymphoma, NOS||Disease|| || || || || ||HD|| | + | |T-lymphoblastic leukaemia / lymphoma, NOS||Disease|| || || || || ||HD|| || |
− | | | + | | |
+ | | | ||
|- | |- | ||
|Early T-precursor lymphoblastic leukaemia / lymphoma | |Early T-precursor lymphoblastic leukaemia / lymphoma | ||
Line 1,271: | Line 1,436: | ||
| | | | ||
|HD | |HD | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,283: | Line 1,449: | ||
| | | | ||
|SK | |SK | ||
+ | | | ||
| | | | ||
| | | | ||
| | | | ||
|- | |- | ||
− | |T-large granular lymphocytic leukaemia||Disease||*Michelle Don, MD, MS|| || || || ||SK|| | + | |T-large granular lymphocytic leukaemia||Disease||*Michelle Don, MD, MS|| || || || ||SK|| || |
− | | | + | | |
+ | | | ||
|- | |- | ||
− | |NK-large granular lymphocytic leukaemia||Disease||Michelle Don, MD|| || || || ||SK|| | + | |NK-large granular lymphocytic leukaemia||Disease||Michelle Don, MD|| || || || ||SK|| || |
− | | | + | | |
+ | | | ||
|- | |- | ||
− | |Adult T-cell leukaemia/lymphoma||Disease||Prasad R. Kopparapu, PhD and Ferrin C. Wheeler, PhD, FACMG Vanderbilt University Medical Center|| || || || ||SK|| | + | |Adult T-cell leukaemia/lymphoma||Disease||Prasad R. Kopparapu, PhD and Ferrin C. Wheeler, PhD, FACMG Vanderbilt University Medical Center|| || || || ||SK|| || |
− | | | + | | |
+ | | | ||
|- | |- | ||
− | |Sezary syndrome||Disease||Madison E. Hannay, DO, Medical University of South Carolina Tingting Barrett, MD, Medical University of South Carolina Daynna J. Wolff, PhD, Medical University of South Carolina|| || || || ||SK|| | + | |Sezary syndrome||Disease||Madison E. Hannay, DO, Medical University of South Carolina Tingting Barrett, MD, Medical University of South Carolina Daynna J. Wolff, PhD, Medical University of South Carolina|| || || || ||SK|| || |
− | | | + | | |
+ | | | ||
|- | |- | ||
− | |Aggressive NK-cell leukaemia||Disease||Shanelle De Lancy, MD, Shashirekha Shetty, PhD|| || || || ||SK|| | + | |Aggressive NK-cell leukaemia||Disease||Shanelle De Lancy, MD, Shashirekha Shetty, PhD|| || || || ||SK|| || |
− | | | + | | |
+ | | | ||
|- | |- | ||
− | |Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder||Disease|| || || || || ||SK|| | + | |Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder||Disease|| || || || || ||SK|| || |
− | | | + | | |
+ | | | ||
|- | |- | ||
− | |Primary cutaneous acral CD8-positive T-cell lymphoproliferative disorder||Disease|| || || || || ||SK|| | + | |Primary cutaneous acral CD8-positive T-cell lymphoproliferative disorder||Disease|| || || || || ||SK|| || |
− | | | + | | |
+ | | | ||
|- | |- | ||
− | |Mycosis fungoides||Disease||Jane Scribner, MD and Daynna J. Wolff, PhD|| || || || ||SK|| | + | |Mycosis fungoides||Disease||Jane Scribner, MD and Daynna J. Wolff, PhD|| || || || ||SK|| || |
− | | | + | | |
+ | | | ||
|- | |- | ||
− | |Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Lymphomatoid papulosis||Disease|| || || || || ||SK|| | + | |Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Lymphomatoid papulosis||Disease|| || || || || ||SK|| || |
− | | | + | | |
+ | | | ||
|- | |- | ||
− | |Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Primary cutaneous anaplastic large cell lymphoma||Disease||Theresa Spivey, MD, Shashirekha Shetty, PhD|| || || || ||SK|| | + | |Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Primary cutaneous anaplastic large cell lymphoma||Disease||Theresa Spivey, MD, Shashirekha Shetty, PhD|| || || || ||SK|| || |
− | | | + | | |
+ | | | ||
|- | |- | ||
− | |Subcutaneous panniculitis-like T-cell lymphoma||Disease|| || || || || ||SK|| | + | |Subcutaneous panniculitis-like T-cell lymphoma||Disease|| || || || || ||SK|| || |
− | | | + | | |
+ | | | ||
|- | |- | ||
− | |Primary cutaneous gamma/delta T-cell lymphoma||Disease|| || || || || ||SK|| | + | |Primary cutaneous gamma/delta T-cell lymphoma||Disease|| || || || || ||SK|| || |
− | | | + | | |
+ | | | ||
|- | |- | ||
− | |Primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma||Disease|| || || || || ||SK|| | + | |Primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma||Disease|| || || || || ||SK|| || |
− | | | + | | |
+ | | | ||
|- | |- | ||
− | |Primary cutaneous peripheral T-cell lymphoma, NOS||Disease|| || || || || ||SK|| | + | |Primary cutaneous peripheral T-cell lymphoma, NOS||Disease|| || || || || ||SK|| || |
− | | | + | | |
+ | | | ||
|- | |- | ||
− | |Indolent T-cell lymphoma of the gastrointestinal tract||Disease||Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD|| || || || ||SK|| | + | |Indolent T-cell lymphoma of the gastrointestinal tract||Disease||Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD|| || || || ||SK|| || |
− | | | + | | |
+ | | | ||
|- | |- | ||
− | |Indolent NK-cell lymphoproliferative disorder of the gastrointestinal tract||Disease|| || || || || ||SK|| | + | |Indolent NK-cell lymphoproliferative disorder of the gastrointestinal tract||Disease|| || || || || ||SK|| || |
− | | | + | | |
+ | | | ||
|- | |- | ||
− | |Enteropathy-associated T-cell lymphoma||Disease||*Derick Okwan-Duodu, MD, PhD *Sumire Kitahara, MD|| || || || ||SK|| | + | |Enteropathy-associated T-cell lymphoma||Disease||*Derick Okwan-Duodu, MD, PhD *Sumire Kitahara, MD|| || || || ||SK|| || |
− | | | + | | |
+ | | | ||
|- | |- | ||
− | |Monomorphic epitheliotropic intestinal T-cell lymphoma||Disease||Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD|| || || || ||SK|| | + | |Monomorphic epitheliotropic intestinal T-cell lymphoma||Disease||Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD|| || || || ||SK|| || |
− | | | + | | |
+ | | | ||
|- | |- | ||
− | |Intestinal T-cell lymphoma, NOS||Disease||Derick Okwan MD, PhD (Stanford Medicine, CA) Sumire Kitahara MD (Cedars-Sinai, CA)|| || || || ||SK|| | + | |Intestinal T-cell lymphoma, NOS||Disease||Derick Okwan MD, PhD (Stanford Medicine, CA) Sumire Kitahara MD (Cedars-Sinai, CA)|| || || || ||SK|| || |
− | | | + | | |
+ | | | ||
|- | |- | ||
− | |Hepatosplenic T-cell lymphoma||Disease||*Michelle Don, MD, MS|| || || || ||SK|| | + | |Hepatosplenic T-cell lymphoma||Disease||*Michelle Don, MD, MS|| || || || ||SK|| || |
− | | | + | | |
+ | | | ||
|- | |- | ||
− | |ALK-positive anaplastic large cell lymphoma||Disease|| || || || || ||SK|| | + | |ALK-positive anaplastic large cell lymphoma||Disease|| || || || || ||SK|| || |
− | | | + | | |
+ | | | ||
|- | |- | ||
− | |ALK-negative anaplastic large cell lymphoma||Disease||Miguel Gonzalez Mancera, MD Sumire Kitahara, MD Cedars-Sinai, Los Angeles, CA|| || || || ||SK|| | + | |ALK-negative anaplastic large cell lymphoma||Disease||Miguel Gonzalez Mancera, MD Sumire Kitahara, MD Cedars-Sinai, Los Angeles, CA|| || || || ||SK|| || |
− | | | + | | |
+ | | | ||
|- | |- | ||
− | |Breast implant-associated anaplastic large cell lymphoma||Disease||Derick Okwan-Duodu, MD, PhD; Sumire Kitahara, MD Cedars-Sinai Medical Center|| || || || ||SK|| | + | |Breast implant-associated anaplastic large cell lymphoma||Disease||Derick Okwan-Duodu, MD, PhD; Sumire Kitahara, MD Cedars-Sinai Medical Center|| || || || ||SK|| || |
− | | | + | | |
+ | | | ||
|- | |- | ||
− | |Nodal TFH cell lymphoma, angioimmunoblastic-type||Disease||* Sara Akhavanfard, M.D., Ph.D. * Ruthann Pfau, Ph.D., FACMG|| || || || ||SK|| | + | |Nodal TFH cell lymphoma, angioimmunoblastic-type||Disease||* Sara Akhavanfard, M.D., Ph.D. * Ruthann Pfau, Ph.D., FACMG|| || || || ||SK|| || |
− | | | + | | |
+ | | | ||
|- | |- | ||
− | |Nodal TFH cell lymphoma, follicular-type||Disease|| || || || || ||SK|| | + | |Nodal TFH cell lymphoma, follicular-type||Disease|| || || || || ||SK|| || |
− | | | + | | |
+ | | | ||
|- | |- | ||
− | |Nodal TFH cell lymphoma, NOS||Disease||Hans Magne Hamnvåg, MD Kamran Mirza, MD, PhD|| || || || ||SK|| | + | |Nodal TFH cell lymphoma, NOS||Disease||Hans Magne Hamnvåg, MD Kamran Mirza, MD, PhD|| || || || ||SK|| || |
− | | | + | | |
+ | | | ||
|- | |- | ||
− | |Peripheral T-cell lymphoma, NOS||Disease|| || || || || ||SK|| | + | |Peripheral T-cell lymphoma, NOS||Disease|| || || || || ||SK|| || |
− | | | + | | |
+ | | | ||
|- | |- | ||
− | |EBV-positive nodal T- and NK-cell lymphoma||Disease|| || || || || ||SK|| | + | |EBV-positive nodal T- and NK-cell lymphoma||Disease|| || || || || ||SK|| || |
− | | | + | | |
+ | | | ||
|- | |- | ||
− | |Extranodal NK/T-cell lymphoma||Disease|| || || || || ||SK|| | + | |Extranodal NK/T-cell lymphoma||Disease|| || || || || ||SK|| || |
− | | | + | | |
+ | | | ||
|- | |- | ||
− | |Severe mosquito bite allergy||Disease|| || || || || ||SK|| | + | |Severe mosquito bite allergy||Disease|| || || || || ||SK|| || |
− | | | + | | |
+ | | | ||
|- | |- | ||
− | |Hydroa vacciniforme lymphoproliferative disorder||Disease|| || || || || ||SK|| | + | |Hydroa vacciniforme lymphoproliferative disorder||Disease|| || || || || ||SK|| || |
− | | | + | | |
+ | | | ||
|- | |- | ||
− | |Systemic chronic active EBV disease||Disease|| || || || || ||SK|| | + | |Systemic chronic active EBV disease||Disease|| || || || || ||SK|| || |
− | | | + | | |
+ | | | ||
|- | |- | ||
− | |Systemic EBV-positive T-cell lymphoma of childhood||Disease||*Lisa A. Lansdon, PhD & Linda D. Cooley, MD, MBA|| || || || ||SK|| | + | |Systemic EBV-positive T-cell lymphoma of childhood||Disease||*Lisa A. Lansdon, PhD & Linda D. Cooley, MD, MBA|| || || || ||SK|| || |
− | | | + | | |
+ | | | ||
|- | |- | ||
|CHAPTER 6 (STROMA-DERIVED NEOPLASMS OF LYMPHOID TISSUES) | |CHAPTER 6 (STROMA-DERIVED NEOPLASMS OF LYMPHOID TISSUES) | ||
Line 1,391: | Line 1,591: | ||
| | | | ||
----<br /> | ----<br /> | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,408: | Line 1,609: | ||
| | | | ||
|GC | |GC | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,420: | Line 1,622: | ||
| | | | ||
|GC | |GC | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,432: | Line 1,635: | ||
| | | | ||
|GC | |GC | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,444: | Line 1,648: | ||
| | | | ||
|GC | |GC | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,456: | Line 1,661: | ||
| | | | ||
|GC | |GC | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,468: | Line 1,674: | ||
| | | | ||
|GC | |GC | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,480: | Line 1,687: | ||
| | | | ||
|GC | |GC | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,489: | Line 1,697: | ||
| | | | ||
----<br /> | ----<br /> | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,498: | Line 1,707: | ||
| | | | ||
|- | |- | ||
− | |Fanconi anaemia||Disease|| || || || || ||NA|| | + | |Fanconi anaemia||Disease|| || || || || ||NA|| || |
− | | | + | | |
+ | | | ||
|- | |- | ||
− | |Bloom syndrome||Disease|| || || || || ||NA|| | + | |Bloom syndrome||Disease|| || || || || ||NA|| || |
− | | | + | | |
+ | | | ||
|- | |- | ||
− | |Ataxia-telangiectasia syndrome||Disease|| || || || || ||NA|| | + | |Ataxia-telangiectasia syndrome||Disease|| || || || || ||NA|| || |
− | | | + | | |
+ | | | ||
|- | |- | ||
− | |RASopathies||Disease|| || || || || ||NA|| | + | |RASopathies||Disease|| || || || || ||NA|| || |
− | | | + | | |
+ | | | ||
|} | |} |
Revision as of 14:46, 17 December 2023
Disease (5th Edition) | Page Type | Author (5th edition) | Date Assigned to Author (5th Edition) | Target Completion Date (5th Edition) | Author Content (5th Edition)(Pending or Complete) | Date Completed by Author (5th Edition) | Associate Editor | Date of Last Editor Review | Notes | Correlated Prior Disease Name (4th Edition) | Correlated Prior Author (4th Edition) |
---|---|---|---|---|---|---|---|---|---|---|---|
CHAPTER 2 (MYELOID PROLIFERATIONS AND NEOPLASMS) |
|
|
|||||||||
Clonal haematopoiesis | Disease | Fabiola Quintero-Rivera (FQR) | |||||||||
Clonal cytopenias of undetermined significance | Disease | FQR | |||||||||
Chronic myeloid leukaemia | Disease | Jack Reid, MD (University of California, Irvine) Mark Evans, MD (University of California, Irvine) Fabiola Quintero-Rivera, MD (University of California, Irvine) | FQR | ||||||||
Chronic neutrophilic leukaemia | Disease | Anamaria Munteanu, MD, Ph.D**, Harbor-UCLA Medical Center, Joseph J. Merlo Jr, MD. Ph.D**, Ashion Analytics, Fabiola Quintero-Rivera, University of California Irvine **contributed equally | FQR | ||||||||
Chronic eosinophilic leukaemia | Disease | Chelsea D. Kramish; Daynna J.Wolff Pending Review* | FQR | ||||||||
Polycythaemia vera | Disease | Gokce A. Toruner, MD, PhD UT MD Anderson Cancer Center | FQR | ||||||||
Essential thrombocythaemia | Disease | Rebecca Smith, PhD, Director, Genetics Associates, Nashville, TN | FQR | ||||||||
Primary myelofibrosis | Disease | T. Niroshi Senaratne, UCLA | FQR | ||||||||
Juvenile myelomonocytic leukaemia | Disease | Assistant Professor, Pathology Associate Director | Division of Molecular Pathology, Genetics and Genomics Duke University Health System Clinical Laboratories | FQR | ||||||||
Myeloproliferative neoplasm, NOS | Disease | Thomas Lee, MD, PhD, University of California, Los Angeles | FQR | ||||||||
Cutaneous mastocytosis | Disease | S. Shawn Liu, MD, PhD and Thuy Phung, MD, PhD | FQR | ||||||||
Systemic mastocytosis | Disease | Abdullah Osme, MD, University Hospitals Cleveland Medical Center, Case Western Reserve University Shashi Shetty, Ph.D. FACMG, FCCMG, University Hospitals Cleveland Medical Center, Case Western Reserve University | FQR | ||||||||
Mast cell sarcoma | Disease | Jordan Lowery, MD and Thuy Phung, MD, PhD Department of Pathology, University of South Alabama, Mobile, AL | FQR | ||||||||
Myelodysplastic neoplasm with low blasts and 5q deletion | Disease | FQR | |||||||||
Myelodysplastic neoplasm with low blasts and SF3B1 mutation | Disease | FQR | |||||||||
Myelodysplastic neoplasm with biallelic TP53 inactivation | Disease | FQR | |||||||||
Myelodysplastic neoplasm with low blasts | Disease | FQR | |||||||||
Myelodysplastic neoplasm, hypoplastic | Disease | FQR | |||||||||
Myelodysplastic neoplasm with increased blasts | Disease | Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG Division of Human Genetics, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH, 45229, USA. | FQR | ||||||||
Childhood myelodysplastic neoplasm with low blasts | Disease | Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG Division of Human Genetics, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH, 45229, USA. | FQR | ||||||||
Childhood myelodysplastic neoplasm with increased blasts | Disease | Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG Division of Human Genetics, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH, 45229, USA. | FQR | ||||||||
Chronic myelomonocytic leukaemia | Disease | Linsheng Zhang, MD, PhD | FQR | ||||||||
Myelodysplastic/myeloproliferative neoplasm with neutrophilia | Disease | Linsheng Zhang, MD, PhD | FQR | ||||||||
Myelodysplastic/myeloproliferative neoplasm with SF3B1 mutation and thrombocytosis | Disease | Anamaria Munteanu, MD, Ph.D, Harbor-UCLA Medical Center, Fabiola Quintero-Rivera, University of California Irvine | FQR | ||||||||
Myelodysplastic/myeloproliferative neoplasm, NOS | Disease | Ruth MacKinnon PhD Victorian Cancer Cytogenetics Service Melbourne, Australia | FQR | ||||||||
Myeloid/lymphoid neoplasm with PDGFRA rearrangement | Disease | Jay Alden, DO | FQR | ||||||||
Myeloid/lymphoid neoplasm with PDGFRB rearrangement | Disease | Christopher Sullivan, MD, MPH and Daynna J. Wolff, PhD | FQR | ||||||||
Myeloid/lymphoid neoplasm with FGFR1 rearrangement | Disease | Yanna Ding, MD PhD | FQR | ||||||||
Myeloid/lymphoid neoplasm with JAK2 rearrangement | Disease | Jessica Snider, M.D. and Daynna J. Wolff, PhD | FQR | ||||||||
Myeloid/lymphoid neoplasm with FLT3 rearrangement | Disease | FQR | |||||||||
Myeloid/lymphoid neoplasm with ETV6::ABL1 fusion | Disease | FQR | |||||||||
Myeloid/lymphoid neoplasms with other tyrosine kinase fusion genes | Disease | FQR | |||||||||
Acute promyelocytic leukaemia with PML::RARA fusion | Disease | Yiming Zhong, Ph.D., Megan Piazza, Ph.D., and Shashi Shetty, Ph.D. | Jennelle Hodge (JH)/ Malini Sathanoori (MS) | ||||||||
Acute myeloid leukaemia with RUNX1::RUNX1T1 fusion | Disease | Christine Bryke, MD Beth Israel Deaconess Medical Center, Boston, MA |
JH_MS | ||||||||
Acute myeloid leukaemia with CBFB::MYH11 fusion | Disease | Christine Bryke, MD Beth Israel Deaconess Medical Center, Boston, MA |
JH_MS | ||||||||
Acute myeloid leukaemia with DEK::NUP214 fusion | Disease | JH_MS | |||||||||
Acute myeloid leukaemia with RBM15::MRTFA fusion | Disease | Jennelle C. Hodge, PhD, FACMG | JH_MS | ||||||||
Acute myeloid leukaemia with BCR::ABL1 fusion | Disease | Kay Weng Choy MBBS, Monash Medical Centre | JH_MS | ||||||||
Acute myeloid leukaemia with KMT2A rearrangement | Disease | Megan Piazza, Ph.D., Yiming Zhong, Ph.D., Shashi Shetty, Ph.D. | JH_MS | ||||||||
Acute myeloid leukaemia with MECOM rearrangement | Disease | JH_MS | |||||||||
Acute myeloid leukaemia with NUP98 rearrangement | Disease | JH_MS | |||||||||
Acute myeloid leukaemia with NPM1 mutation | Disease | Xinjie Xu, PhD, FACMG | JH_MS | ||||||||
Acute myeloid leukaemia with CEBPA mutation | Disease | Paul Defazio, MSc, Monash Health | JH_MS | ||||||||
Acute myeloid leukaemia, myelodysplasia-related | Disease | Fei Yang, MD, FACMG Oregon Health & Science University, Portland, OR |
JH_MS | ||||||||
Acute myeloid leukaemia with other defined genetic alterations | Disease | JH_MS | |||||||||
Acute myeloid leukaemia with minimal differentiation | Disease | Celeste Eno, PhD, Cedars Sinai Medical Center, Los Angeles, Fabiola Quintero-Rivera, MD, FACMG, University of California Irvine | JH_MS | ||||||||
Acute myeloid leukaemia without maturation | Disease | Jennelle C. Hodge, PhD, FACMG | JH_MS | ||||||||
Acute myeloid leukaemia with maturation | Disease | Jennelle C. Hodge, PhD, FACMG | JH_MS | ||||||||
Acute basophilic leukaemia | Disease | Ashwini Yenamandra PhD FACMG | JH_MS | ||||||||
Acute myelomonocytic leukaemia | Disease | Fei Yang, MD, FACMG Oregon Health & Science University, Portland, OR |
JH_MS | ||||||||
Acute monocytic leukaemia | Disease | Fei Yang, MD, FACMG Oregon Health & Science University, Portland, OR |
JH_MS | ||||||||
Acute erythroid leukaemia | Disease | Ashwini Yenamandra PhD FACMG | JH_MS | ||||||||
Acute megakaryoblastic leukaemia | Disease | Fei Yang, MD, FACMG Oregon Health & Science University, Portland, OR |
JH_MS | ||||||||
Myeloid sarcoma | Disease | Yalda Naeini, MD, School of Medicine at University of California Los Angeles Fabiola Quintero-Rivera, MD, FACMG, School of Medicine at University of California Irvine | JH_MS | ||||||||
Myeloid neoplasm post cytotoxic therapy | Disease | Shawn A. Silver, DO, Shashi Shetty, Ph.D. | JH_MS | ||||||||
Myeloid neoplasms associated with germline predisposition | Disease | JH_MS | |||||||||
Myeloid proliferations associated with Down syndrome | Disease | Linda D Cooley, MD, MBA, Children's Mercy Hospital, Kansas City, MO | JH_MS | ||||||||
Mixed-phenotype acute leukaemia with BCR::ABL1 fusion | Disease | Tracy Tucker, PhD, FCCMG | JH_MS | ||||||||
Mixed-phenotype acute leukaemia with KMT2A rearrangement | Disease | Tracy Tucker, PhD, FCCMG | JH_MS | ||||||||
Acute leukaemia of ambiguous lineage with other defined genetic alterations | Disease | JH_MS | |||||||||
Mixed-phenotype acute leukaemia, B/myeloid | Disease | Priyatharsini Nirmalanantham, MD and Shashi Shetty, PhD | JH_MS | ||||||||
Mixed-phenotype acute leukaemia, T/myeloid | Disease | Narsis Attar, MD, PhD, Fabiola Quintero-Rivera, MD University of California, Irvine | JH_MS | ||||||||
Mixed-phenotype acute leukaemia, rare types | Disease | Elicia Goodale, MD, Medical University of South Carolina Daynna Wolff, PhD, Medical University of South Carolina | JH_MS | ||||||||
Acute leukaemia of ambiguous lineage, NOS | Disease | JH_MS | |||||||||
Acute undifferentiated leukaemia | Disease | Amelia Nakanishi, MD and Shashi Shetty, PhD | JH_MS | ||||||||
CHAPTER 3 (HISTIOCYTIC/DENRITIC CELL NEOPLASMS) |
|
|
|||||||||
Mature plasmacytoid dendritic cell proliferation associated with myeloid neoplasm | Disease | Greg Corboy (GC) | |||||||||
Blastic plasmacytoid dendritic cell neoplasm | Disease | Hao Liu, MD and Daynna J. Wolff, PhD | GC | ||||||||
Langerhans cell histiocytosis | Disease | Dr Malaika Perchard BSci(MedSci), MBBS, FRACP, FRCPA, (Paediatric Haematologist) Pathology Queensland | GC | ||||||||
Langerhans cell sarcoma | Disease | Dr Malaika Perchard BSci(MedSci), MBBS, FRACP, FRCPA, (Paediatric Haematologist) Pathology Queensland | GC | ||||||||
Indeterminate dendritic cell tumour | Disease | GC | |||||||||
Interdigitating dendritic cell sarcoma | Disease | GC | |||||||||
Juvenile xanthogranuloma | Disease | GC | |||||||||
Erdheim-Chester disease | Disease | GC | |||||||||
Rosai-Dorfman Disease | Disease | GC | |||||||||
ALK-positive histiocytosis | Disease | GC | |||||||||
Histiocytic sarcoma | Disease | Marie-France Gagnon, MD, Mayo Clinic, Xinjie Xu, PhD FACMG, Mayo Clinic | GC | ||||||||
CHAPTER 4 (B-CELL LYMPHOID PROLIFERATIONS AND LYMPHOMAS) |
|
|
|||||||||
Reactive B-cell rich lymphoid proliferations that can mimic lymphoma | Disease | GC | |||||||||
IgG4-related disease | Disease | GC | |||||||||
Unicentric Castleman disease | Disease | GC | |||||||||
Idiopathic multicentric Castleman disease | Disease | GC | |||||||||
KSHV/HHV8-associated multicentric Castleman disease | Disease | Sudha Arumugam, MD | GC | ||||||||
B-lymphoblastic leukaemia/lymphoma | Disease | Holli Drendel (HD) | |||||||||
B-lymphoblastic leukaemia/lymphoma with high hyperdiploidy | Disease | Afia Hasnain, MBBS, PhD; Yassmine Akkari, PhD, FACMG | HD | ||||||||
B-lymphoblastic leukaemia/lymphoma with hypodiploidy | Disease | Ashwini Yenamandra PhD FACMG Lisa Smith PhD FACMG Yassmine Akkari PhD FACMG | HD | ||||||||
B-lymphoblastic leukaemia/lymphoma with iAMP21 | Disease | Holli M. Drendel, PhD, FACMGG, Carolinas Pathology Group, Charlotte | HD | ||||||||
B-lymphoblastic leukaemia/lymphoma with BCR::ABL1 fusion | Disease | Afia Hasnain, MBBS, PhD; Yassmine Akkari, PhD, FACMG | HD | ||||||||
B-lymphoblastic leukaemia/lymphoma with BCR::ABL1-like features | Disease | Mark G. Evans, MD, University of California, Irvine Fabiola Quintero-Rivera, MD, University of California, Irvine | HD | ||||||||
B lymphoblastic leukaemia/lymphoma with KMT2A rearrangement | Disease | Yassmine Akkari Nicolas Millan | HD | ||||||||
B lymphoblastic leukaemia/lymphoma with ETV6::RUNX1 fusion | Disease | Marilena Melas, PhD; Yassmine Akkari, PhD, FACMG Cancer Category/Type B-Lymphoblastic Leukemia/Lymphoma | HD | ||||||||
B-lymphoblastic leukaemia/lymphoma with ETV6::RUNX1-like features | Disease | HD | |||||||||
B lymphoblastic leukaemia/lymphoma with TCF3::PBX1 fusion | Disease | Binu Porath, PhD. Vanderbilt University Medical Center, Nashville, TN Linda D. Cooley, MD, MBA. Children's Mercy Kansas City, Kansas City, MO | HD | ||||||||
B lymphoblastic leukaemia/lymphoma with IGH::IL3 fusion | Disease | Binu Porath, PhD. Vanderbilt University Medical Center, Nashville, TN Linda D. Cooley, MD, MBA. Children's Mercy Kansas City, Kansas City, MO | HD | ||||||||
B lymphoblastic leukaemia/lymphoma with TCF3::HLF fusion | Disease | HD | |||||||||
B-lymphoblastic leukaemia/lymphoma with other defined genetic alterations | Disease | HD | |||||||||
B-lymphoblastic leukaemia/lymphoma, NOS | Disease | HD | |||||||||
Monoclonal B-cell lymphocytosis | Disease | Shivani Golem (SG) | |||||||||
Chronic lymphocytic leukaemia/small lymphocytic lymphoma | Disease | Jamie Nagy, PhD, University of Iowa Honey Reddi, PhD | SG | ||||||||
Hairy cell leukaemia | Disease | *Snehal Patel, MD, PhD | SG | ||||||||
Splenic marginal zone lymphoma | Disease | *Snehal Patel, MD, PhD | SG | ||||||||
Splenic diffuse red pulp small B-cell lymphoma | Disease | *Snehal Patel, MD, PhD | SG | ||||||||
Splenic B-cell lymphoma/leukaemia with prominent nucleoli | Disease | *Snehal Patel, MD, PhD | SG | ||||||||
Lymphoplasmacytic lymphoma | Disease | Kapitolina Semenova, MD, Jack Reid, MD, Fabiola Quintero-Rivera, MD Departments of Pathology, Laboratory Medicine, and *Pediatrics, Division of Genetic and Genomic Medicine, University of California, Irvine (UCI) | SG | ||||||||
Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue | Disease | SG | |||||||||
Primary cutaneous marginal zone lymphoma | Disease | SG | |||||||||
Nodal marginal zone lymphoma | Disease | Andrew Ly, DO and Shivani Golem, PhD, FACMG | SG | ||||||||
Paediatric nodal marginal zone lymphoma | Disease | * Kathleen M. Schieffer, PhD * Ruthann Pfau, PhD | SG | ||||||||
In situ follicular B-cell neoplasm | Disease | Rachel D. Burnside, PhD, MBA, FACMGG | SG | ||||||||
Follicular lymphoma | Disease | Ruthann Pfau, PhD, FACMG, Nationwide Children's Hospital Rachel D. Burnside, PhD, MBA, FACMG, University of Florida | SG | ||||||||
Paediatric-type follicular lymphoma | Disease | *Kathleen M. Schieffer, PhD *Ruthann Pfau, PhD, FACMG | SG | ||||||||
Duodenal-type follicular lymphoma | Disease | SG | |||||||||
Primary cutaneous follicle centre lymphoma | Disease | Linlin Gao, MD, PhD and Shivani Golem, PhD, FACMG | SG | ||||||||
In situ mantle cell neoplasm | Disease | Rina Kansal, MD; Versiti Blood Center of Wisconsin | SG | ||||||||
Mantle cell lymphoma | Disease | * Mahsa Khanlari, MD * Zhenya Tang, MD, PhD The University Of Texas MD Anderson Cancer Center, Department of Hematopathology, Houston, Texas | SG | ||||||||
Leukaemic non-nodal mantle cell lymphoma | Disease | SG | |||||||||
Transformations of indolent B-cell lymphomas | Disease | SG | |||||||||
Diffuse large B-cell lymphoma, NOS | Disease | Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center | GC | ||||||||
T-cell/histiocyte-rich large B-cell lymphoma | Disease | GC | |||||||||
Diffuse large B-cell lymphoma / high grade B-cell lymphoma with MYC and BCL2 rearrangements | Disease | Kate Berry, MBBS, BBus (Hons), Pathology Queensland | GC | ||||||||
ALK-positive large B-cell lymphoma | Disease | Manando Nakasaki, MD, PhD (University of California, Irvine) Fabiola Quintero-Rivera, MD, FACMG (University of California, Irvine) | GC | ||||||||
Large B-cell lymphoma with IRF4 rearrangement | Disease | *Afia Hasnain, MBBS, PhD | GC | ||||||||
High grade B-cell lymphoma with 11q aberrations | Disease | Lauren Shealy, MD, Medical University of South Carolina Daynna Wolff, PhD, Medical University of South Carolina | GC | ||||||||
Lymphomatoid granulomatosis | Disease | GC | |||||||||
EBV-positive diffuse large B-cell lymphoma | Disease | GC | |||||||||
Diffuse large B-cell lymphoma associated with chronic inflammation | Disease | GC | |||||||||
Fibrin-associated large B-cell lymphoma | Disease | GC | |||||||||
Fluid overload-associated large B-cell lymphoma | Disease | GC | |||||||||
Plasmablastic lymphoma | Disease | Mark Evans, MD (University of California, Irvine) Fabiola Quintero-Rivera, MD (University of California, Irvine) | GC | ||||||||
Primary large B-cell lymphoma of immune-privileged sites | Disease | Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center | GC | ||||||||
Primary cutaneous diffuse large B-cell lymphoma, leg type | Disease | GC | |||||||||
Intravascular large B-cell lymphoma | Disease | Kate Berry, MBBS, BBus (Hons), Pathology Queensland | GC | ||||||||
Primary mediastinal large B-cell lymphoma | Disease | GC | |||||||||
Mediastinal grey zone lymphoma | Disease | GC | |||||||||
High-grade B-cell lymphoma, NOS | Disease | Aiko Otsubo, PhD, Indiana University | GC | ||||||||
Burkitt lymphoma | Disease | Becky Leung, MBBS (Hons), BSc, Pathology Queensland | GC | ||||||||
Primary effusion lymphoma | Disease | GC | |||||||||
KSHV/HHV8-positive diffuse large B-cell lymphoma | Disease | GC | |||||||||
KSHV/HHV8-positive germinotropic lymphoproliferative disorder | Disease | GC | |||||||||
Hyperplasias arising in immune deficiency/dysregulation | Disease | GC | |||||||||
Polymorphic lymphoproliferative disorders arising in immune deficiency / dysregulation | Disease | Anna Shestakova, MD, PhD, Fellow, University of Utah/ARUP Laboratories Fabiola Quintero-Rivera, MD, Professor, University of California Irvine (UCI) | GC | ||||||||
EBV-positive mucocutaneous ulcer | Disease | GC | |||||||||
Lymphomas arising in immune deficiency / dysregulation | Disease | GC | |||||||||
Inborn error of immunity-associated lymphoid proliferations and lymphomas | Disease | GC | |||||||||
Classic Hodgkin lymphoma | Disease | Patricia V. Hernandez, M.D., Washington University School of Medicine | GC | ||||||||
Nodular lymphocyte predominant Hodgkin lymphoma | Disease | GC | |||||||||
Cold agglutinin disease | Disease | SG | |||||||||
IgM monoclonal gammopathy of undetermined significance | Disease | SG | |||||||||
Non-IgM monoclonal gammopathy of undetermined significance | Disease | SG | |||||||||
Monoclonal gammopathy of renal significance | Disease | SG | |||||||||
Immunoglobulin-related (AL) amyloidosis | Disease | Heather E. Williams, PhD, MS, PgD, ErCLG | SG | ||||||||
Monoclonal immunoglobulin deposition disease | Disease | Chen Yang, MD, PhD, University of Michigan | SG | ||||||||
Mu heavy chain disease | Disease | SG | |||||||||
Gamma heavy chain disease | Disease | Manisha Brahmbhatt-Sutariya Asst. Professor, Dept. of Pathology and Human Anatomy Technical Supervisor, Clinical Genetics Laboratory Loma Linda University, Medical Center, CA | SG | ||||||||
Alpha heavy chain disease | Disease | SG | |||||||||
Plasmacytoma | Disease | SG | |||||||||
Plasma cell myeloma / multiple myeloma | Disease | *Huan Mo, MD, MS *Zhenya Tang, MD, PhD The University Of Texas MD Anderson Cancer Center, Department of Hematopathology, Houston, Texas | SG | ||||||||
Plasma cell neoplasms with associated paraneoplastic syndrome | Disease | Sohini Anand, MBBS Tharanga Niroshini Senaratne, PhD | SG | ||||||||
CHAPTER 5 (T-CELL AND NK-CELL LYMPHOID PROLIFERATIONS AND LYMPHOMAS) |
|
|
|||||||||
Kikuchi-Fujimoto disease | Disease | Sumi Kitahara (SK) | |||||||||
Autoimmune lymphoproliferative syndrome | Disease | SK | |||||||||
Indolent T-lymphoblastic proliferation | Disease | SK | |||||||||
T-lymphoblastic leukaemia / lymphoma, NOS | Disease | HD | |||||||||
Early T-precursor lymphoblastic leukaemia / lymphoma | Disease | Fei Yang, MD, FACMG, Kaiser Permanente Northwest | HD | ||||||||
T-prolymphocytic leukaemia | Disease | SK | |||||||||
T-large granular lymphocytic leukaemia | Disease | *Michelle Don, MD, MS | SK | ||||||||
NK-large granular lymphocytic leukaemia | Disease | Michelle Don, MD | SK | ||||||||
Adult T-cell leukaemia/lymphoma | Disease | Prasad R. Kopparapu, PhD and Ferrin C. Wheeler, PhD, FACMG Vanderbilt University Medical Center | SK | ||||||||
Sezary syndrome | Disease | Madison E. Hannay, DO, Medical University of South Carolina Tingting Barrett, MD, Medical University of South Carolina Daynna J. Wolff, PhD, Medical University of South Carolina | SK | ||||||||
Aggressive NK-cell leukaemia | Disease | Shanelle De Lancy, MD, Shashirekha Shetty, PhD | SK | ||||||||
Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder | Disease | SK | |||||||||
Primary cutaneous acral CD8-positive T-cell lymphoproliferative disorder | Disease | SK | |||||||||
Mycosis fungoides | Disease | Jane Scribner, MD and Daynna J. Wolff, PhD | SK | ||||||||
Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Lymphomatoid papulosis | Disease | SK | |||||||||
Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Primary cutaneous anaplastic large cell lymphoma | Disease | Theresa Spivey, MD, Shashirekha Shetty, PhD | SK | ||||||||
Subcutaneous panniculitis-like T-cell lymphoma | Disease | SK | |||||||||
Primary cutaneous gamma/delta T-cell lymphoma | Disease | SK | |||||||||
Primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma | Disease | SK | |||||||||
Primary cutaneous peripheral T-cell lymphoma, NOS | Disease | SK | |||||||||
Indolent T-cell lymphoma of the gastrointestinal tract | Disease | Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD | SK | ||||||||
Indolent NK-cell lymphoproliferative disorder of the gastrointestinal tract | Disease | SK | |||||||||
Enteropathy-associated T-cell lymphoma | Disease | *Derick Okwan-Duodu, MD, PhD *Sumire Kitahara, MD | SK | ||||||||
Monomorphic epitheliotropic intestinal T-cell lymphoma | Disease | Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD | SK | ||||||||
Intestinal T-cell lymphoma, NOS | Disease | Derick Okwan MD, PhD (Stanford Medicine, CA) Sumire Kitahara MD (Cedars-Sinai, CA) | SK | ||||||||
Hepatosplenic T-cell lymphoma | Disease | *Michelle Don, MD, MS | SK | ||||||||
ALK-positive anaplastic large cell lymphoma | Disease | SK | |||||||||
ALK-negative anaplastic large cell lymphoma | Disease | Miguel Gonzalez Mancera, MD Sumire Kitahara, MD Cedars-Sinai, Los Angeles, CA | SK | ||||||||
Breast implant-associated anaplastic large cell lymphoma | Disease | Derick Okwan-Duodu, MD, PhD; Sumire Kitahara, MD Cedars-Sinai Medical Center | SK | ||||||||
Nodal TFH cell lymphoma, angioimmunoblastic-type | Disease | * Sara Akhavanfard, M.D., Ph.D. * Ruthann Pfau, Ph.D., FACMG | SK | ||||||||
Nodal TFH cell lymphoma, follicular-type | Disease | SK | |||||||||
Nodal TFH cell lymphoma, NOS | Disease | Hans Magne Hamnvåg, MD Kamran Mirza, MD, PhD | SK | ||||||||
Peripheral T-cell lymphoma, NOS | Disease | SK | |||||||||
EBV-positive nodal T- and NK-cell lymphoma | Disease | SK | |||||||||
Extranodal NK/T-cell lymphoma | Disease | SK | |||||||||
Severe mosquito bite allergy | Disease | SK | |||||||||
Hydroa vacciniforme lymphoproliferative disorder | Disease | SK | |||||||||
Systemic chronic active EBV disease | Disease | SK | |||||||||
Systemic EBV-positive T-cell lymphoma of childhood | Disease | *Lisa A. Lansdon, PhD & Linda D. Cooley, MD, MBA | SK | ||||||||
CHAPTER 6 (STROMA-DERIVED NEOPLASMS OF LYMPHOID TISSUES) |
|
|
|||||||||
Follicular dendritic cell sarcoma | Disease | Anna Heimes Dillon, MD and Shivani Golem, PhD, FACMG | GC | ||||||||
EBV-positive inflammatory follicular dendritic cell sarcoma | Disease | GC | |||||||||
Fibroblastic reticular cell tumour | Disease | GC | |||||||||
Intranodal palisaded myofibroblastoma | Disease | GC | |||||||||
Littoral cell angioma | Disease | GC | |||||||||
Splenic hamartoma | Disease | GC | |||||||||
Sclerosing angiomatoid nodular transformation (SANT) of spleen | Disease | GC | |||||||||
CHAPTER 7 (GENETIC TUMOUR SYNDROMES) |
|
|
|||||||||
Fanconi anaemia | Disease | NA | |||||||||
Bloom syndrome | Disease | NA | |||||||||
Ataxia-telangiectasia syndrome | Disease | NA | |||||||||
RASopathies | Disease | NA |